Price Movement and Market Context
The stock closed at ₹8,535.30 on 8 May 2026, marking a 1.98% increase from the previous close of ₹8,369.45. Intraday volatility was evident, with a high of ₹8,567.50 and a low of ₹8,383.35. While the current price remains below its 52-week high of ₹10,653.05, it comfortably exceeds the 52-week low of ₹7,630.00, indicating a recovery phase within a broader trading range.
Comparatively, Astrazeneca Pharma India Ltd has outperformed the Sensex over multiple periods. The stock delivered a 3.87% return over the past week versus the Sensex’s 1.21%, and a robust 9.76% gain over the last month compared to the Sensex’s 4.33%. Year-to-date, the stock has declined by 5.27%, though this is less severe than the Sensex’s 8.66% fall. Over longer horizons, Astrazeneca’s returns are impressive, with a 10-year gain of 645.80% dwarfing the Sensex’s 208.56%.
Technical Trend Analysis
The technical trend for Astrazeneca Pharma India Ltd has shifted from bearish to mildly bearish, signalling a tentative improvement but still reflecting caution. The daily moving averages remain mildly bearish, suggesting that short-term momentum is yet to fully recover. However, weekly and monthly Bollinger Bands indicate bullish tendencies, implying that price volatility is currently supporting upward movement within a defined range.
The Moving Average Convergence Divergence (MACD) indicator presents a mixed picture: weekly readings are mildly bullish, hinting at potential upward momentum in the near term, while monthly MACD remains mildly bearish, reflecting longer-term caution. This divergence suggests that while short-term traders may find opportunities, longer-term investors should remain vigilant.
Momentum and Oscillator Indicators
The Relative Strength Index (RSI) on both weekly and monthly charts shows no clear signal, hovering in neutral zones without indicating overbought or oversold conditions. This neutrality suggests that the stock is not currently experiencing extreme momentum pressures, which could imply a consolidation phase.
Meanwhile, the Know Sure Thing (KST) oscillator remains bearish on the weekly timeframe and mildly bearish monthly, reinforcing the notion of subdued momentum. The Dow Theory assessment aligns with this, showing a mildly bearish weekly trend and no definitive monthly trend, further underscoring the cautious stance among market participants.
Volume and On-Balance Volume (OBV) Insights
On-Balance Volume (OBV) analysis reveals a mildly bearish weekly trend, indicating that volume flow is not strongly supporting price advances. The monthly OBV shows no clear trend, suggesting that volume dynamics are currently indecisive. This volume behaviour may limit the sustainability of any short-term price rallies.
Strong fundamentals, solid momentum, fair price – This Large Cap from the NBFC sector checks every box for our Top 1%. This should definitely be on your radar!
- - Complete fundamentals package
- - Technical momentum confirmed
- - Reasonable valuation entry
Mojo Score and Rating Revision
MarketsMOJO’s latest assessment assigns Astrazeneca Pharma India Ltd a Mojo Score of 42.0, categorising it as a Sell. This represents a downgrade from the previous Hold rating as of 2 January 2026. The downgrade reflects the mixed technical signals and the mildly bearish trend shifts, particularly on longer-term indicators such as monthly MACD and KST. The small-cap status of the company also adds to the risk profile, as smaller companies tend to exhibit higher volatility and sensitivity to market fluctuations.
Long-Term Performance and Sector Context
Despite recent technical caution, Astrazeneca Pharma India Ltd’s long-term performance remains impressive. Over five years, the stock has appreciated by 124.03%, more than double the Sensex’s 58.20% gain. Over three years, the outperformance is even more pronounced, with a 166.79% return versus the Sensex’s 27.50%. This strong historical performance underscores the company’s resilience and growth potential within the Pharmaceuticals & Biotechnology sector.
However, the sector itself is facing mixed headwinds, including regulatory scrutiny and pricing pressures, which may be contributing to the cautious technical outlook. Investors should weigh these sectoral challenges alongside Astrazeneca’s individual momentum signals.
Key Technical Levels to Watch
From a price perspective, the immediate support lies near the recent low of ₹8,383.35, while resistance is encountered around the intraday high of ₹8,567.50. A sustained break above this resistance could validate the weekly bullish Bollinger Band signals and weekly MACD’s mildly bullish stance, potentially triggering a short-term rally. Conversely, a drop below support levels may reinforce the mildly bearish daily moving averages and KST readings, signalling further downside risk.
Investor Takeaway
In summary, Astrazeneca Pharma India Ltd is navigating a complex technical landscape. The stock exhibits a blend of mildly bullish and bearish indicators, with short-term momentum showing tentative improvement but longer-term signals remaining cautious. The downgrade to Sell by MarketsMOJO reflects this nuanced outlook, advising investors to exercise prudence.
Long-term investors may find comfort in the company’s strong historical returns and sector positioning, but should remain alert to evolving technical signals and sector dynamics. Traders might consider the weekly bullish indicators for tactical entries, while monitoring volume and momentum oscillators for confirmation.
Astrazeneca Pharma India Ltd or something better? Our SwitchER feature analyzes this small-cap Pharmaceuticals & Biotechnology stock and recommends superior alternatives based on fundamentals, momentum, and value!
- - SwitchER analysis complete
- - Superior alternatives found
- - Multi-parameter evaluation
Conclusion
Astrazeneca Pharma India Ltd’s technical parameters reveal a stock at a crossroads. While short-term indicators such as weekly MACD and Bollinger Bands suggest mild bullishness, the prevailing mildly bearish daily moving averages and monthly momentum oscillators counsel caution. The recent downgrade to Sell by MarketsMOJO further emphasises the need for careful evaluation before committing fresh capital.
Investors should closely monitor key support and resistance levels, volume trends, and momentum oscillators to gauge the sustainability of any price moves. Given the stock’s strong long-term track record, a balanced approach combining technical vigilance with fundamental analysis is advisable.
Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Start Today
